• 1
    Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M 1996 Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:1251112516.
  • 2
    Gelb BD, Moissoglu K, Zhang J, Martignetti JA, Bromme D, Desnick RJ 1996 Cathepsin K: Isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene. Biochem Mol Med 59:200206.
  • 3
    Gelb BD, Shi GP, Chapman HA, Desnick RJ 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:12361238.
  • 4
    Johnson MR, Polymeropoulos MH, Vos HL, Ortiz De Luna RI, Francomano CA 1996 A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Research 6:10501055.
  • 5
    Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I 1999 Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:16541663.
  • 6
    Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, Von Figura K 1998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:1345313458.
  • 7
    Bossard MJ, Tomaszek TA, Levy MA, Ijames CF, Huddleston MJ, Briand J, Thompson S, Halpert S, Veber DF, Carr SA, Meek TD, Tew DG 1999 Mechanism of inhibition of cathepsin K by potent, selective 1,5-diacylcarbohydrazides: A new class of mechanism-based inhibitors of thiol proteases. Biochemistry 38:1589315902.
  • 8
    Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M 1997 Peptide aldehyde inhibitors of cathepsin k inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 12:13961406.
  • 9
    Marquis RW, Ru Y, Yamashita DS, Oh HJ, Yen J, Thompson SK, Carr TJ, Levy MA, Tomaszek TA, Ijames CF, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, D'Alessio KJ, McQueney MS, Veber DF 1999 Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K. Bioorg Med Chem 7:581588.
  • 10
    Marquis RW, Yamashita DS, Ru Y, Locastro SM, Oh HJ, Erhard KF, Desjarlais RL, Head MS, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, Tomaszek TA, Levy MA, Veber DF 1998 Conformationally constrained 1,3-diamino ketones—a series of potent inhibitors of the cysteine protease cathepsin K. J Med Chem 41:35633567.
  • 11
    Inui T, Ishibashi O, Inaoka T, Origane Y, Kumegawa M, Kokubo T, Yamamura T 1997 Cathepsin k antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem 272:81098112.
  • 12
    Veber DF, Yamashita DS, Oh H, Smith BR, Salyers K, Levy M, Lee C, Marzulli A, Smith P, Tomaszek T, Tew D, McQueney M, Stroup GB, Lark MW, James IE 2000 Novel Inhibitors of the Osteoclast Specific Cysteine Protease, CathepsinK, FieldGB, TamJP, BaranyG (eds.). Kluwer, Dordricht, The Netherlands, pp. 453455.
  • 13
    McQueney MS, Feild J, Hanning CR, Brun K, Ramachandran K, Connor J, Drake F, Jones CS, Amegadzie BY 1998 Cynomolgus monkey (Macaca fascicularis) cathepsin K: Cloning, expression, purification, and activation. Protein Express Purification 14:387394.
  • 14
    Stroup GB, Hoffman SJ, Vasko-Moser JA, Lechowska BA, Jenkins EL, Dare LC, Gowen M 2001 Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: A short-term model for evaluation of antiresorptive therapy. Bone 28:532537.
  • 15
    Marquis RW, Ru Y, Zeng J, Trout RE, Locastro SM, Gribble AD, Witherington J, Fenwick AE, Garnier B, Tomaszek T, Tew D, Hemling ME, Quinn CJ, Smith WW, Zhao B, McQueney MS, Janson CA, D'Alessio K, Veber DF 2001 Cyclic ketone inhibitors of the cysteine protease cathepsin K. J Med Chem 44:725736.
  • 16
    Cleland WW 1979 Statistical analysis of enzyme kinetic data. Methods Enzymol 63:103138.
  • 17
    Dodds RA, James IE, Rieman D, Ahern R, Hwang SM, Connor JR, Thompson SD, Veber DF, Drake FH, Holmes S, Lark MW, Gowen M 2001 Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J Bone Miner Res 16:476486.
  • 18
    James IE, Dodds RA, Olivera DL, Nuttall ME, Gowen M 1996 Human osteoclastoma-derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 11:14531460.
  • 19
    James IE, Lark MW, Zembryki D, Lee-Rykaczewski EV, Hwang SM, Tomaszek TA, Belfiore P, Gowen M 1999 Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents. J Bone Miner Res 14:15621569.
  • 20
    Foged NT, Delaisse JM, Hou P, Lou H, Sato T, Winding B, Bonde M 1996 Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay. J Bone Miner Res 11:226237.
  • 21
    Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S 1998 Application of a new serum assay for type i collagen cross-linked n-telopeptides—assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102106.
  • 22
    Atley LM, Mort JS, Lalumiere M, Eyre DR 2000 Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone 26:241247.
  • 23
    Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaisse JM 1998 The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:3234732352.
  • 24
    Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP 1998 Human cathepsin K cleaves native type i and ii collagens at the n-terminal end of the triple helix. Biochem J 331:727732.
  • 25
    Everts V, Delaisse JM, Korper W, Beertsen W 1998 Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res 13:14201430.
  • 26
    James IE, Marquis RW, Blake SM, Hwang SM, Gress CJ, Ru Y, Zembryki D, Yamashita DS, McQueney MS, Tomaszek TA, Oh HJ, Gowen M, Veber DF, Lark MW 2001 Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro. J Biol Chem 276:1150711511.
  • 27
    Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA 1999 Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. J Clin Endocrinol Metab 84:30763081.
  • 28
    Rosen CJ, Chesnut CH, Mallinak NJS 1997 The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:19041910.
  • 29
    Ravn P, Clemmesen B, Christiansen C 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 24:237244.
  • 30
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitlandramsey L, Karpf DB 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women—a randomized clinical trial. J Bone Miner Res 13:14311438.
  • 31
    Frost HM 1979 Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Relat Res 143:227244.
  • 32
    Pacifici R, Mcmurtry C, Vered I, Rupich R, Avioli LV 1988 Coherence therapy does not prevent axial bone loss in osteoporotic women: A preliminary comparative study. J Clin Endocrinol Metab 66:747753.
  • 33
    Steiniche T, Hasling C, Charles P, Eriksen EF, Melsen F, Mosekilde L 1991 The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime. Bone 12:155163.